Trial site
Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, 363000, ChinaNot linked to an institution yet
- 17running trials
- 6closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Recruiting7 trials
- Active, not recruiting6 trials
- Completed6 trials
- Not yet recruiting4 trials
- Lead sponsor
- Capital Medical University3 trials
- Akeso2 trials
- Beijing Northland Biotech. Co., Ltd.2 trials
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
- BeiGene1 trial
- and 13 more
Running trials
Not yet recruiting
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
NCT07897955· Fujian Medical University Union Hospital· Source
Contact: Tingyu Yi
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Li Lin, Bachelor
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Contact: Yuanmao Huang, Site 0327
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314· Capital Medical University· Source
Contact: Tingyu Yi
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792· Guangdong Provincial People's Hospital· Source
Contact: Shanying Chen
Active, not recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301· Capital Medical University· Source
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Li Lin, Bachelor
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Li Lin, M.D.
Active, not recruiting
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532· Phase 3· Biotheus Inc.· Source
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT)
NCT06559241· Phase 3· Capital Medical University· Source
Contact: Tingyu Yi
Active, not recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
NCT06360458· Phase 3· Wan-Jin Chen· Source
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Contact: Zhifang Yao, M.D.
Active, not recruiting
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994· Phase 2· BeiGene· Source
Recruiting
Oriental Research AlliaNce of Acute Ischemic Stroke Given Endovascular Treatment
NCT05024292· Shanghai Jiao Tong University Affiliated Sixth People's Hospital· Source
Contact: Wenhuo Chen, MD
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036· Phase 3· Takeda· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error